Limits...
Statins and the risk of lung cancer: a meta-analysis.

Tan M, Song X, Zhang G, Peng A, Li X, Li M, Liu Y, Wang C - PLoS ONE (2013)

Bottom Line: Study-specific risk estimates were pooled using a random-effects model.Low evidence of publication bias was found.However, statistically significant heterogeneity was found among cohort studies and among case-control studies.

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.

ABSTRACT

Purpose: Several epidemiologic studies have evaluated the association between statins and lung cancer risk, whereas randomized controlled trials (RCTs) on cardiovascular outcomes provide relevant data as a secondary end point. We conducted a meta-analysis of all relevant studies to examine this association.

Methods: A systematic literature search up to March 2012 was performed in PubMed database. Study-specific risk estimates were pooled using a random-effects model.

Results: Nineteen studies (5 RCTs and 14 observational studies) involving 38,013 lung cancer cases contributed to the analysis. They were grouped on the basis of study design, and separate meta-analyses were conducted. There was no evidence of an association between statin use and risk of lung cancer either among RCTs (relative risk [RR] 0.91, 95% confidence interval [CI] 0.76-1.09), among cohort studies (RR 0.94, 95% CI 0.82-1.07), or among case-control studies (RR 0.82, 95% CI 0.57-1.16). Low evidence of publication bias was found. However, statistically significant heterogeneity was found among cohort studies and among case-control studies. After excluding the studies contributing most to the heterogeneity, summary estimates were essentially unchanged.

Conclusion: The results of our meta-analysis suggest that there is no association between statin use and the risk of lung cancer.

Show MeSH

Related in: MedlinePlus

Flow diagram of study identification.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585354&req=5

pone-0057349-g001: Flow diagram of study identification.

Mentions: Our initial search strategy retrieved a total of 1459 citations. After the titles and abstracts were screened, 1429 articles were excluded because they were laboratory studies, review articles, or irrelevant to the current study. We identified 30 potentially relevant articles concerning statin use in relation to lung cancer risk. Eight publications were excluded because they investigated the association of statin with risk of total cancer and lung cancer was not among collected data [16]–[23]. Two articles were excluded because they did not provide RR estimate [24], [25] and one article was excluded because it reported on similar population [26]. Finally, 19 articles [27]–[45] concerning statin use and lung cancer risk (including 5 RCT studies and 14 observational studies) were included in this meta-analysis (Figure 1). We performed this meta-analysis in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement (File 1) [46].


Statins and the risk of lung cancer: a meta-analysis.

Tan M, Song X, Zhang G, Peng A, Li X, Li M, Liu Y, Wang C - PLoS ONE (2013)

Flow diagram of study identification.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585354&req=5

pone-0057349-g001: Flow diagram of study identification.
Mentions: Our initial search strategy retrieved a total of 1459 citations. After the titles and abstracts were screened, 1429 articles were excluded because they were laboratory studies, review articles, or irrelevant to the current study. We identified 30 potentially relevant articles concerning statin use in relation to lung cancer risk. Eight publications were excluded because they investigated the association of statin with risk of total cancer and lung cancer was not among collected data [16]–[23]. Two articles were excluded because they did not provide RR estimate [24], [25] and one article was excluded because it reported on similar population [26]. Finally, 19 articles [27]–[45] concerning statin use and lung cancer risk (including 5 RCT studies and 14 observational studies) were included in this meta-analysis (Figure 1). We performed this meta-analysis in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement (File 1) [46].

Bottom Line: Study-specific risk estimates were pooled using a random-effects model.Low evidence of publication bias was found.However, statistically significant heterogeneity was found among cohort studies and among case-control studies.

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.

ABSTRACT

Purpose: Several epidemiologic studies have evaluated the association between statins and lung cancer risk, whereas randomized controlled trials (RCTs) on cardiovascular outcomes provide relevant data as a secondary end point. We conducted a meta-analysis of all relevant studies to examine this association.

Methods: A systematic literature search up to March 2012 was performed in PubMed database. Study-specific risk estimates were pooled using a random-effects model.

Results: Nineteen studies (5 RCTs and 14 observational studies) involving 38,013 lung cancer cases contributed to the analysis. They were grouped on the basis of study design, and separate meta-analyses were conducted. There was no evidence of an association between statin use and risk of lung cancer either among RCTs (relative risk [RR] 0.91, 95% confidence interval [CI] 0.76-1.09), among cohort studies (RR 0.94, 95% CI 0.82-1.07), or among case-control studies (RR 0.82, 95% CI 0.57-1.16). Low evidence of publication bias was found. However, statistically significant heterogeneity was found among cohort studies and among case-control studies. After excluding the studies contributing most to the heterogeneity, summary estimates were essentially unchanged.

Conclusion: The results of our meta-analysis suggest that there is no association between statin use and the risk of lung cancer.

Show MeSH
Related in: MedlinePlus